Sangamo Therapeutics (SGMOQ) EV to CFO (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted EV to CFO of 3.96 for Q4 2025, up 42.04% on a QoQ basis from 6.84 in Q3 2025, and up 92.42% year-over-year from 2.06 in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) EV to CFO (2010 - 2025) Analysis & Trends
Sangamo Therapeutics has reported EV to CFO for 16 years, with the latest figure at 3.96 in Q4 2025.
- On a quarterly basis, EV to CFO rose 92.42% year-over-year to 3.96 in Q4 2025; TTM through Dec 2025 was 1.0, a 61.86% increase from a year earlier, with the FY2025 full-year figure at 1.0, up 61.86% from the prior year.
- EV to CFO was 3.96 for Q4 2025 at Sangamo Therapeutics, up from 6.84 in the prior quarter.
- The five-year high for EV to CFO was 12.1 in Q3 2024, with the low at 52.28 in Q4 2024.
- Average EV to CFO over 5 years is 8.63, with a median of 6.5 recorded in 2022.
- The largest YoY upside for EV to CFO was 2126.98% in 2024 against a maximum downside of 5081.44% in 2024.
- Over 5 years, EV to CFO stood at 13.62 in 2021, then jumped by 45.52% to 7.42 in 2022, then surged by 86.4% to 1.01 in 2023, then tumbled by 5081.44% to 52.28 in 2024, then soared by 92.42% to 3.96 in 2025.
- The last three EV to CFO figures came in at 3.96 (Q4 2025), 6.84 (Q3 2025), and 6.86 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Sangamo Therapeutics | 43.74 Mn | 22.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -3.96 |
| Sep 30, 2025 | -6.84 |
| Jun 30, 2025 | -6.86 |
| Mar 31, 2025 | -4.92 |
| Dec 31, 2024 | -52.28 |
| Sep 30, 2024 | 12.10 |
| Jun 30, 2024 | -1.75 |
| Mar 31, 2024 | -1.72 |
| Dec 31, 2023 | -1.01 |
| Sep 30, 2023 | 0.54 |
| Jun 30, 2023 | -1.44 |
| Mar 31, 2023 | -3.38 |
| Dec 31, 2022 | -7.42 |
| Sep 30, 2022 | -9.13 |
| Jun 30, 2022 | -6.16 |
| Mar 31, 2022 | -9.06 |
| Dec 31, 2021 | -13.62 |
| Sep 30, 2021 | -14.96 |
| Jun 30, 2021 | -23.02 |
| Mar 31, 2021 | -17.72 |